Dendreon sold its cancer drug in Chapter 11 for $415m; two years later it fetched $820m

Dendreon made medical history in April 2010 when the FDA approved Provenge, the first cellular immunotherapy for prostate cancer — a personalized treatment that trained a patient's own immune cells. But the drug's launch economics never matched the science: Medicare reimbursement lagged, revenues plateaued, and the company carried roughly $660 million of convertible notes it could not refinance. On November 10, 2014, Dendreon filed for Chapter 11 protection.

The company and its bondholders chose speed over a standalone reorganization: a Section 363 sale with Valeant Pharmaceuticals as stalking-horse bidder. On February 23, 2015, Valeant completed the purchase of Dendreon's assets for $415 million net of cash received — $495 million gross, including about $50 million in Valeant stock — taking worldwide rights to Provenge through a court-supervised process that cleared the capital structure.

Valeant's own collapse then forced a second sale, and this is where the value showed itself. On January 9, 2017, China's Sanpower Group agreed to buy Dendreon, and the deal closed on June 29, 2017 for $819.9 million in cash — nearly double what Valeant had paid. Provenge had by then treated more than 20,000 patients, carried broad Medicare and commercial reimbursement, and remained the only FDA-approved cellular immunotherapy for prostate cancer.

Valeant's $415 million stalking-horse bid bought worldwide Provenge rights in February 2015; Sanpower paid $819.9 million in cash for the whole business in June 2017.

The 363 process converted an unserviceable convert-heavy balance sheet into a clean asset sale without the two-to-three-year delay of a negotiated exchange.

A stalking-horse bid set a floor and preserved going-concern value, keeping Provenge's manufacturing sites and patient base intact rather than piecing the company out.

Provenge's clinical franchise — first-in-class status and 20,000 treated patients — was worth more to a patient owner than to Dendreon's creditors on a deadline.

Valeant's distress created the discount: Sanpower's $819.9 million exit price showed the 2015 sale price reflected the seller's clock, not the asset's ceiling.

A first-of-its-kind product is not a business until reimbursement and debt service line up. A clean Section 363 sale preserved the drug's value for a buyer who could hold it longer.

Under Sanpower, Dendreon kept its US team and pushed Provenge toward China and Southeast Asia, leveraging Sanpower's healthcare network. The episode became a case study in bankruptcy value recovery: the drug that bankruptcy supposedly marked as a failure returned nearly 100 percent more within two years of its court sale. For biotech boards, Dendreon remains the reference point on matching launch financing to slow reimbursement curves — Provenge's science was never the problem.